Cited by 102Sirtuins and Resveratrol in MedicineCardiac Fibrosis and RemodelingCardiovascular Function and Risk Factors

Resveratrol Treatment of Mice With Pressure-Overload–Induced Heart Failure Improves Diastolic Function and Cardiac Energy Metabolism

Open access
Sung, Miranda M., Das, Subhash K., Levasseur, Jody, Byrne, Nikole J., Fung, David, Kim, Ty T., Masson, Grant, Boisvenue, Jamie +3 more·2015·Circulation: Heart Failure

Abstract

Background—: Although resveratrol has multiple beneficial cardiovascular effects, whether resveratrol can be used for the treatment and management of heart failure (HF) remains unclear. In the current study, we determined whether resveratrol treatment of mice with established HF could lessen the detrimental phenotype associated with pressure-overload–induced HF and identified physiological and molecular mechanisms contributing to this. Methods and Results—: C57Bl/6 mice were subjected to either sham or transverse aortic constriction surgery to induce HF. Three weeks post surgery, a cohort of mice with established HF (% ejection fraction <45) was administered resveratrol (≈320 mg/kg per day). Despite a lack of improvement in ejection fraction, resveratrol treatment significantly increased median survival of mice with HF, lessened cardiac fibrosis, reduced gene expression of several disease markers for hypertrophy and extracellular matrix remodeling that were upregulated in HF, promoted beneficial remodeling, and improved diastolic function. Resveratrol treatment of mice with established HF also restored the levels of mitochondrial oxidative phosphorylation complexes, restored cardiac AMP-activated protein kinase activation, and improved myocardial insulin sensitivity to promote glucose metabolism and significantly improved myocardial energetic status. Finally, noncardiac symptoms of HF, such as peripheral insulin sensitivity, vascular function, and physical activity, were improved with resveratrol treatment. Conclusions—: Resveratrol treatment of mice with established HF lessens the severity of the HF phenotype by lessening cardiac fibrosis, improving molecular and structural remodeling of the heart, and enhancing diastolic function, vascular function, and energy metabolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.114.001677

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sung, M. M., Das, S. K., Levasseur, J., Byrne, N. J., Fung, D., Kim, T. T., Masson, G., Boisvenue, J., Soltys, C.-L., Oudit, G. Y., & Dyck, J. R. B.
Affiliations
University of Alberta (CA)
Venue
Circulation: Heart Failure
Published
2015-01
Volume
8
Issue
1
Pages
128-137
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2156697471
Cited by
102
References
53
Citations by year
2026: 8 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 8
FWCI
4.59
Type
journal article
Language
en
Open access
Locations
  • Circulation Heart Failure (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alberta Innovates
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
resveratrol, heart failure, pressure overload, transverse aortic constriction, diastolic function, myocardial fibrosis, cardiac remodeling, cardiac hypertrophy, extracellular matrix remodeling, mitochondrial oxidative phosphorylation, AMPK, myocardial energy metabolism, peripheral insulin sensitivity, vascular function, survival
MeSH terms
Resveratrol, Animals, Disease Models, Animal, Energy Metabolism, Male, Mice, Inbred C57BL, Myocardial Contraction, Myocardium, Ribonucleotide Reductases, Stilbenes, Stroke Volume, Vasodilator Agents, Ventricular Function, Left, Ventricular Remodeling, Mice, Heart Failure, Diastolic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review